

# What's New in Antibiotic Allergies?

David A. Khan, MD

Program Director, Allergy & Immunology Fellowship Program  
Professor of Medicine and Pediatrics  
University of Texas Southwestern Medical Center  
Dallas, TX



1

## Disclosure

I have no financial interests or relationships to disclose.



2

01

Gain an understanding of the spectrum of antibiotic allergies

02

Be able to identify historical features suggestive of a low likelihood for drug allergy

03

Gain an understanding of updates on beta-lactam allergy and cross-reactivity

04

Review 7 Key Points


## Learning Objectives

3

Key Point 1

# Adverse Drug Reactions $\neq$ Drug Allergy

4



5

Key Point #2

# There are Many Different Types of Drug Allergies and Different Types of Drug Rashes Help with Classification & Management

6

## Case A

This patient developed this rash **30 minutes** after taking amoxicillin



7

## Case B


This patient developed a rash **5 days** after taking amoxicillin



8

# Which Patient Is at Risk for Anaphylaxis If Amoxicillin Is Administered Again?

- A. Patient A
- B. Patient B
- C. Both A & B
- D. Neither



**TABLE E1. Spectrum of cutaneous drug reactions**

**Common cutaneous drug reactions**

- Exanthems
- Urticaria
- Angioedema
- Fixed drug eruption
- Pruritus
- Acneform
- SCARs
- DRESS
- SJS/TEN
- AGEP


**Less common cutaneous drug reactions**

- Acanthosis nigricans
- Alopecia
- Aphthous stomatitis
- Black hairy tongue
- Bullous eruptions
- Erythema nodosum
- Exfoliative dermatitis
- Gingival hyperplasia
- Lichenoid eruptions
- Lupus erythematosus
- Phototoxic/photoallergic
- Pigmentation
- Pityriasis rosea-like eruptions
- Psoriasis
- Purpura
- Vasculitis


Khan DA. J Allergy Clin Immunol 2012;130:1225-e6.

**Urticaria & Angioedema**  
(Case A)

Multiple mechanisms:  
IgE, pseudoallergic,  
serum sickness,  
bradykinin



Urticaria



Angioedema

Joshi SR, Khan DA. Pediatric Allergy: Principles and Practice. 4th ed. 2021

11

**IgE Mediated Reactions**

**Onset**

- Usually minutes up to 6 hours after drug exposure
- Requires prior exposure to drug or cross-reacting drug (sensitization)

**Symptoms**

- Urticaria, flushing, pruritus, angioedema, anaphylaxis

Rash resolves without peeling, or changes in pigmentation

12

# Pseudoallergic Reactions

Resemble true IgE allergic reactions but IgE not involved

## Pathophysiology

- Non-specific mast cell degranulation
- Activation of MRGPRX<sub>2</sub> receptor

Onset usually minutes to hour after exposure (like IgE)

- May occur with 1<sup>st</sup> exposure


Urticaria, flushing, pruritus, rarely hypotension

## Examples

- Opiates, **vancomycin**, **ciprofloxacin**
- Vancomycin Infusion Reaction (preferred terminology)

Premedication with antihistamines is helpful

13




14

# Morbiliform Drug Eruptions (Case B)

- Most common drug allergic reaction
- Pathophysiology mixed: Often T cell mediated
- Onset variable often within days or longer
- Pruritic, usually starts on trunk and spreads to extremities in a symmetric fashion
- Often resolves with scaling/peeling
- Does not evolve into anaphylaxis

15


Acute (Hospital)                      Days Later (Home)



# Morbiliform Drug Eruption

16





## Cutaneous Drug Eruptions

17

### Severe Cutaneous Adverse Drug Reactions (SCAR)

- SJS/TEN, DRESS, AGEP
- Patients are ill
  - Fever, other systemic symptoms
- Mortality 5 to >30%
- Require multidisciplinary care

**DIAGNOSIS OF CLINICAL PHENOTYPE**

MACULOPAPULAR ERUPTIONS · CONTACT DERMATITIS · FDE · AGEP · DRESS · CUTANEOUS VASCULITIS · BULLOUS FDE · SINGLE ORGAN INVOLVEMENT · SJS/TEN

MPE	FDE	AGEP	DRESS	TEN

FROM A MILD REACTION
TO A SEVERE REACTION

Lehloenyha RL et al. J Allergy Clin Immunol Pract. 2020;8(9):2878-95..

18

Non-Cutaneous  
Organ Specific  
Drug Allergic  
Reactions

	Clinical Features	Examples of causative agents
Hematologic	hemolytic anemia, thrombocytopenia, granulocytopenia	penicillin, sulfonamides
Hepatic	hepatitis, cholestatic jaundice	sulfonamides, phenothiazines
Pulmonary	pneumonitis, fibrosis	nitrofurantoin, bleomycin, methotrexate
Renal	interstitial nephritis, membranous glomerulonephritis	penicillin, sulfonamides, allopurinol


Khan DA, Solensky R. J Allergy Clin Immunol 2010;125(2 Suppl 2):S126-37.

19

The Best  
Tool in Our  
Toolbox

# History Taking in Drug Allergy

20



21

Features Suggestive of **True** Drug Allergy

- Objective findings
  - Rash
  - Wheezing, hypoxia
  - Hypotension
- Rational temporal relationship to drug
- "allergy-prone" drug
- Resolution with discontinuation


22

**Features Less Suggestive of Drug Allergy**

- Subjective symptoms only
  - “swelling”, pruritus
  - isolated throat symptoms
- High number of listed drug allergies
- Stereotypical reactions
- History of a remote reaction

23

**Is This Angioedema?**



1 2 3

24

## Testing in Drug Allergy


- Genetic Screening
- Skin Testing
- Drug Challenges

25

### HLA-A\*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms

Katherine C. Konvise, MS,<sup>a</sup> Jason A. Trubiano, MBBS, PhD,<sup>b,c,d</sup> Rebecca Pavlos, PhD,<sup>a</sup> Ian James, PhD,<sup>f</sup> Christian M. Shaffer, BS,<sup>g</sup> Cosmin A. Bejan, PhD,<sup>h</sup> Ryan J. Schutte, PhD,<sup>i</sup> David A. Ostrov, PhD,<sup>j</sup> Mark A. Pilkinton, MD, PhD,<sup>k</sup> Misha Rosenbach, MD,<sup>k</sup> Jeffrey P. Zwerner, MD, PhD,<sup>l</sup> Kristina B. Williams, RN, BSN, CCRP,<sup>j</sup> Jack Bourke, MBBS,<sup>m</sup> Patricia Martinez, MBBS, PhD,<sup>m,n,o</sup> Francois Rwandamuriye, MS,<sup>f</sup> Abha Chopra, PhD,<sup>f</sup> Mark Watson, PhD,<sup>f</sup> Alec J. Redwood, PhD,<sup>f</sup> Katie D. White, MD, PhD,<sup>f</sup> Simon A. Mallal, MBBS,<sup>n,l,i</sup> and Elizabeth J. Phillips, MD<sup>n,l,p</sup>  
*Nashville, Tenn; Heidelberg, Parkville, Nedlands, Murdoch, Perth, and Crawley, Australia; Gainesville, Fla; and Philadelphia, Pa*

**GRAPHICAL ABSTRACT**



26

J Allergy Clin Immunol. 2019;144(1):183-92.

26

## Antibiotic Skin Testing

### Indications

- Most commonly used for high risk patient histories
  - e.g. Anaphylaxis
- Not useful for noncutaneous organ-specific reactions (e.g. AIN, cytopenias, drug-induced liver injury)**

### Specific antibiotics

- Proven accuracy for penicillin
- May be useful to predict tolerance to cephalosporins with disparate R1 groups
- Not helpful for sulfonamides, macrolides, fluoroquinolones, vancomycin etc.

27

## Drug Challenges

### Most common method used to determine tolerance to a drug

### Used in patients with low-risk drug allergy histories

- Reaction > 5-10 years ago
- Benign skin rashes
- Unknown/vague reactions

28

*Practice parameter*


**Drug allergy: A 2022 practice parameter update**

David A. Khan, MD,<sup>a</sup> Aleena Banerji, MD,<sup>b</sup> Kimberly G. Blumenthal, MD, MSc,<sup>b</sup> Elizabeth J. Phillips, MD,<sup>c,d</sup> Roland Solensky, MD,<sup>e</sup> Andrew A. White, MD,<sup>f</sup> Jonathan A. Bernstein, MD,<sup>g</sup> Derek K. Chu, MD, PhD,<sup>h,i,j</sup> Anne K. Ellis, MD,<sup>k</sup> David B. K. Golden, MD,<sup>l</sup> Matthew J. Greenhawt, MD,<sup>m</sup> Caroline C. Horner, MD,<sup>n</sup> Dennis Ledford, MD,<sup>o,p</sup> Jay A. Lieberman, MD,<sup>q</sup> John Oppenheimer, MD,<sup>r</sup> Matthew A. Rank, MD,<sup>s</sup> Marcus S. Shaker, MD, MSc,<sup>t</sup> David R. Stukus, MD,<sup>u,v</sup> Dana Wallace, MD,<sup>w</sup> and Julie Wang, MD<sup>x</sup> *Dallas, Tex; Boston, Mass; Murdoch, Australia; Nashville and Memphis, Tenn; Corvallis, Ore; San Diego, Calif; Cincinnati and Columbus, Ohio; Hamilton and Kingston, Ontario, Canada; Baltimore, Md; Aurora, Colo; St Louis, Mo; Tampa and Fort Lauderdale, Fla; Rutgers, NJ; Scottsdale, Ariz; Lebanon, NH; and New York, NY*

[https://www.jacionline.org/article/S0091-6749\(22\)01186-1/fulltext](https://www.jacionline.org/article/S0091-6749(22)01186-1/fulltext)


Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

29



30

# Drug Allergies in a Boston EHR




N=1.76 million

Penicillin Allergy=12.8%

Zhou L et al. Allergy 2016; 71: 1305-1313.

31

# Decline in Positive Penicillin Skin Tests (Kaiser)



Khan DA. Allergy Asthma Proc. 2020;41(2):82-89.

32



Low Rate (<1%)  
of Positive Skin  
Tests Since 2000  
(Mayo Clinic)

Figure 3: PST Percent Positive ≥ 3x3 Wheal Group





Figure 4: PST Percent Positive ≥ 5x5 Wheal Group



N=30,883

Voelker D et al. J Allergy Clin Immunol Pract. 2020;8(6):1980-1986.e1987.

33

Key Point #3

Most Patients Who  
Really Were Allergic  
to Penicillin in the  
Past, Lose Their  
Allergy Over Time

34

# Why Penicillin Allergy Labels Matter

Castells MC, Khan DA, Phillips EC. NEJM 2019




Figure 4. Health Implications and Burden of the Penicillin-Allergy Label.

35

## PRACTICE CHANGER

### Proactive Penicillin Allergy Delabeling

#### Consensus Based Statement

- We recommend that a proactive effort should be made to delabel a penicillin allergy, if appropriate.

#### Strength of Recommendation

- Strong

#### Certainty of Evidence

- Moderate

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

36

No Need to Test Patients with Invalid Histories of Penicillin Allergy

Consensus Based Statement

- We **recommend against testing in patients with a history inconsistent with penicillin allergy** (such as headache or family history of penicillin allergy), but a 1-step amoxicillin challenge may be offered to patients who are anxious or request additional reassurance to accept the removal of a penicillin allergy label.

Strength of Recommendation

- Strong

Certainty of Evidence

- Moderate

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

37

**PARADIGM SHIFT**

Penicillin Skin Testing Not Required for Most Children

Consensus Based Statement

- We **recommend against penicillin skin testing prior to direct amoxicillin challenge in pediatric patients with a history of benign cutaneous reaction** (such as morbilliform drug eruptions and urticaria).

Strength of Recommendation

- Strong

Certainty of Evidence

- Moderate


38

Direct Amoxicillin Challenges Safe in Children with Penicillin Allergy Label

Original Article

---

**The Safety of the Direct Drug Provocation Test in Beta-Lactam Hypersensitivity in Children: A Systematic Review and Meta-Analysis**



Witchaya Srisuwatchari, MD<sup>a</sup>, Phichayut Phinyo, MD, PhD<sup>b,c,d</sup>, Anca Mirela Chiriac, MD, PhD<sup>e,f</sup>, Surasak Saokaew, PharmD, PhD, BPHCP, FACP, FCPA<sup>g</sup>, and Prapasri Kulalert, MD, PhD<sup>h,i</sup> Bangkok, Chiang Mai, Phayao, and Pathum Thani, Thailand; and Montpellier, France

5% Challenges positive

<1% are immediate reactions

4% delayed rash

Risk of anaphylaxis < 1 in 8000 challenge

Srisuwatchari W et al. J Allergy Clin Immunol Pract. 2023;11(2):506-18.

39

Direct Amoxicillin Challenge May Be Considered for Low Risk Patients Labeled with Penicillin Allergy

PRACTICE CHANGER

Consensus Based Statement

- We suggest that **direct amoxicillin challenge be considered in adults** with a history of distant and benign cutaneous reactions (such as morbilliform drug eruptions and urticaria).

Strength of Recommendation

- Conditional

Certainty of Evidence

- Low

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

40

# Defining Low Risk in Adults



41

JAMA Internal Medicine | Original Investigation

## Development and Validation of a Penicillin Allergy Clinical Decision Rule

Jason A. Trubiano, MBBS, PhD; Sara Vogrin, MBBS, MBiostat; Kyra Y. L. Chua, MBBS, PhD; Jack Bourke, MBBS; James Yun, MBBS, PhD; Abby Douglas, MBBS; Cosby A. Stone, MD; Roger Yu, MD; Lauren Groenendijk, MD; Natasha E. Holmes, MBBS, PhD; Elizabeth J. Phillips, MD

Figure. PEN-FAST Penicillin Allergy Clinical Decision Rule

<b>PEN</b>	Penicillin allergy reported by patient	<input type="checkbox"/> If yes, proceed with assessment
<b>F</b>	Five years or less since reaction <sup>a</sup>	<input type="checkbox"/> 2 points
<b>A</b>	Anaphylaxis or angioedema	<input type="checkbox"/> 2 points
<b>S</b>	Severe cutaneous adverse reaction <sup>b</sup>	
<b>T</b>	Treatment required for reaction <sup>a</sup>	<input type="checkbox"/> 1 point
		<input type="checkbox"/> Total points
<b>Interpretation</b>		
<b>0</b>	Very low risk of positive penicillin allergy test <1% (<1 in 100 patients reporting penicillin allergy)	
<b>1-2</b>	Low risk of positive penicillin allergy test 5% (1 in 20 patients)	
<b>3</b>	Moderate risk of positive penicillin allergy test 20% (1 in 5 patients)	
<b>4-5</b>	High risk of positive penicillin allergy test 50% (1 in 2 patients)	

PEN-FAST Score=0, NPV of 99.4%  
PEN-FAST Score=3, NPV of 96.3%

PEN-FAST Score < 3 excluded severe allergies

JAMA Intern Med. 2020;180(5):745-52.

42

JAMA Internal Medicine | **Original Investigation**


# Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy

## The PALACE Randomized Clinical Trial

Ana Maria Copaescu, MD; Sara Vogrin, MBIostat; Fiona James, BBIomedSci; Kyra Y. L. Chua, PhD; Morgan T. Rose, MBBS; Joseph De Luca, MBBS; Jamie Waldron, MD; Andrew Awad, MD; Jack Godsell, MBBS; Elise Mitri, BPharm; Belinda Lambros, MAdvNursPrac; Abby Douglas, PhD; Rabea Youcef Khoudja, MD; Ghislaine A. C. Isabwe, MD; Genevieve Genest, MD; Michael Fein, MD; Cristine Radojicic, MD; Ann Collier, MD; Patricia Lugar, MD; Cosby Stone, MD; Moshe Ben-Shoshan, MD; Nicholas A. Turner, MD; Natasha E. Holmes, PhD; Elizabeth J. Phillips, MD; Jason A. Trubiano, PhD

JAMA Intern Med. 2023;183(9):944-52.

43



JAMA Intern Med. 2023;183(9):944-52.

44

Simple Low-Risk Definition

### Reaction History

- Rash only
- Unknown
- Childhood

### Time Since Reaction

- >5-10 years

45


Other Populations to Delabel

ICU patients

Pregnant patients

Koo G et al. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1660-3 e2.  
Mak R et al. J Allergy Clin Immunol Pract 2022 Vol. 10 Issue 7 Pages 1919-1921 e1

46



Penicillin Allergy Videos

aaaaai.org/tools-for-the-public/video-library/penicillin-allergy-videos

Annual Meeting | Ask the Expert | Journals | Find An Allergist / Immunologist | Check Pollen Counts | Donate

AAA American Academy of Allergy Asthma & Immunology


Allergist Resources | Practice Management | Professional Education | Conditions & Treatments

Tools For The Public / Video Library / Penicillin Allergy Videos

# Penicillin Allergy Videos

A Penicillin Allergy Direct Challenge can be conducted safely in both the in-patient and clinic settings by physicians and other health care providers. This video series takes an in depth look at how and when to conduct the challenge in both settings as well as for adults and children.

47



### Videos for Adult Inpatient Delabeling

- Assessing the Risk / Taking a Patient History: How to Identify Patients at Low Risk of Having a True Penicillin Allergy
- Penicillin Allergy Challenge in the Inpatient Setting: Implementing Amoxicillin Challenges in the Adult Inpatient Setting
- How to Conduct a Penicillin Challenge in the Hospital
- For Patients: Amoxicillin Challenge: Why Is It Important and How Is It Done?

### Videos for Pediatric Outpatient Delabeling

- For Pediatricians: Why Most Kids Can Safely Undergo Amoxicillin Challenges
- Implementing Amoxicillin Challenges in Your Pediatric Office
- Penicillin Allergy Challenge in the Clinic Setting: How To Conduct An Oral Amoxicillin Challenge in Your Office
- Amoxicillin Challenge: Why Is It Important For My child and How Is It Done?

48




## In a Patient Who Developed Hives After Taking Penicillin, What Is the Risk of Reacting to a Cephalosporin?


- A. 25%
- B. 10%
- C. 5%
- D. <1%

## Penicillin Allergy and Cross-Reactivity with Beta-Lactams

Penicillin Structure



Cephalosporin Structure



Penicillin and Cephalosporin Cross-Reactivity

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

51

Key Point #4



Most All Patients Labeled as Penicillin Allergic Can Take Cephalosporins

52

Original Article

**Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses**

Matthieu Picard, MD, FRCPC<sup>a</sup>, Geneviève Robitaille, PhD<sup>b</sup>, Fatiha Karam, PhD<sup>b</sup>, Jean-Marc Daigle, MSc<sup>b</sup>, François Bédard, MSc<sup>c</sup>, Éric Biron, PhD<sup>c</sup>, Mélanie R. Tardif, PhD<sup>b</sup>, Jonathan Lacombe-Barrios, MD, FRCPC<sup>d</sup>, and Philippe Bégin, MD, PhD, FRCPC<sup>d,e</sup> Montréal, QC, Canada



**If proven allergy to aminopenicillin risk of positive skin test to:**

**aminocephalosporin is 16%**

**unrelated cephalosporin is 2%**

Picard M, et al. J Allergy Clin Immunol Pract. 2019;7(8):2722-38 e5.

53

**Risk of Cephalosporin Cross-Reactivity in Unverified Penicillin Allergy**

- <5% of patients with an unverified penicillin allergy are truly allergic
- ~2% of those who are truly allergic will experience a reaction to a cephalosporin
- the chance of a reaction is very low with a linked probability of approximately 0.1%
  - (0.05x0.02=0.001).

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

54

**PRACTICE CHANGER**

Cephalosporin Administration with Non-Anaphylactic Penicillin Allergy History

Consensus Based Statement

- We suggest that for patients with an **unverified non-anaphylactic penicillin allergy**, a cephalosporin can be administered without testing or additional precautions.

Strength of Recommendation

- Conditional

Certainty of Evidence

- Moderate

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

55


Original Article

**Tolerability of Cefazolin and Cefibuten in Patients with IgE-Mediated Aminopenicillin Allergy**



Antonino Romano, MD<sup>a</sup>, Rocco Luigi Valluzzi, MD<sup>b</sup>, Cristiano Caruso, MD<sup>c</sup>, Alessandra Zaffiro, MD<sup>d</sup>, Donato Quarantino, MD<sup>d</sup>, and Francesco Gaeta, MD, PhD<sup>e</sup> *Catania, Vatican City, and Rome, Italy*

131 subjects	• 98.5% aminopenicillin allergy, <b>78% with anaphylaxis</b>
130/131 had negative cefazolin/ceftibuten skin tests	• 1 subject (outlier) had positive skin tests to all PCN reagents, cephalosporins and carbapenems
129/130 agreed to cefazolin/ceftibuten challenges	• All 129 had negative challenges



Cefazolin and ceftibuten R1 groups dispartate from aminopenicillins

J Allergy Clin Immunol Pract. 2020;8(6):1989-93.e2.

56

**PRACTICE CHANGER**

Cephalosporin Administration with Anaphylactic Penicillin Allergy History

Consensus Based Statement

- We suggest that for patients with a history of **anaphylaxis to penicillin, a non-cross-reactive cephalosporin can be administered without prior testing.**

Strength of Recommendation

- Conditional

Certainty of Evidence

- Moderate

Cefazolin ok even for anaphylactic penicillin allergy history

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.




Original Investigation | Allergy

Association Between Removal of a Warning Against Cephalosporin Use in Patients With Penicillin Allergy and Antibiotic Prescribing

Eric Macy, MD, MS; Thomas A. McCormick, PhD; John L. Adams, PhD; William W. Crawford, MD; Myngoc T. Nguyen, MD; Liem Hoang, PharmD, MS; Victoria Eng, MD; Anna C. Davis, PhD; Elizabeth A. McGlynn, PhD

Figure. Multinomial Logistic Regression of Changes in Antibiotic Use Among Patients With Penicillin Allergies




No significant differences in the rates of anaphylaxis, allergies to new antibiotic classes, antibiotic treatment failure, all-cause mortality, hospital days, and new infections after the change.

Macy E et al. JAMA Netw Open. 2021;4(4):e218367.

## Penicillin Allergy & Carbapenems

In Proven Penicillin Allergy Risk of Reacting to Carbapenem < 1%



Picard M, et al. JACI In Practice. 2019;7(8):2722-38.e5.

59

## PRACTICE CHANGER

Carbapenem Administration with Penicillin Allergy History

### Consensus Based Statement

- We recommend that in **patients with a history of penicillin or cephalosporin allergy, a carbapenem may be administered without prior testing.**

### Strength of Recommendation

- Strong

### Certainty of Evidence

- Moderate




Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

60

Key Point #5

# A Patient Allergic to One Cephalosporin Can Usually Take Other Cephalosporins That Are Structurally Different

61

Group 1		Ceftriaxone, Cefotaxime, Cefepime Cefpodoxime, Cefditoren
Group 2		Cefuroxime
Group 3		Ceftazidime, aztreonam

Khan DA et al. J Allergy Clin Immunol 2019;7(7):2105-14.

62

62

## Identical R1 Side Chains:

## Penicillins and Cephalosporins

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

	Cefazolin (1 <sup>st</sup> )	Cefaclor (2 <sup>nd</sup> )	Cefadroxil (1 <sup>st</sup> )	Cefepime (4 <sup>th</sup> )	Cefotaxime (3 <sup>rd</sup> )	Cefoxitin (2 <sup>nd</sup> )	Cefprozil (2 <sup>nd</sup> )	Ceftazidime (3 <sup>rd</sup> )	Ceftriaxone (3 <sup>rd</sup> )	Cephalexin (1 <sup>st</sup> )	Amoxicillin	Ampicillin	Aztreonam
Cefazolin (1 <sup>st</sup> )	.												
Cefaclor (2 <sup>nd</sup> )		.							X			X	
Cefadroxil (1 <sup>st</sup> )			.			X			X	X			
Cefepime (4 <sup>th</sup> )				.	X			X					
Cefotaxime (3 <sup>rd</sup> )				X	.			X					
Cefoxitin (2 <sup>nd</sup> )						.							
Cefprozil (2 <sup>nd</sup> )			X				.			X			
Ceftazidime (3 <sup>rd</sup> )								.					X
Ceftriaxone (3 <sup>rd</sup> )				X	X				.				
Cephalexin (1 <sup>st</sup> )		X	X							.		X	
Amoxicillin			X				X				.		
Ampicillin		X							X			.	
Aztreonam								X					.

63

Key Point #6

# Patients Allergic to Sulfonamide Antibiotics Can Take Other "Sulfa" and Sulfonamide Non-antibiotic Medications


64



# Sulfonamide Allergy

65

Sulfonamide Antibiotics Are Structurally Different than Non-Antimicrobial Sulfonamides



Antimicrobial sulfonamides			
Sulfamethoxazole	Sulfamerazine	Sulfamethizole	Sulfamoxole
Sulfacetamide	Sulfanilamide	Sulfamerazine	Sulfadiazine
Sulfamethazine	Sulfisoxazole	Sulfapyridine	Sulfasalazine (metabolized to sulfapyridine)
Non-antimicrobial sulfonamides			
Tamulosin	Ibutilide	Sotalol	Topiramate
Acetazolamide	Methazolamide	Dorzoalamide	Celecoxib
Furosemide	Bumetanide	Metalozone	Torseamide
Hydrochlorothiazide	Chlorthalidone	Glimepiride	Glyburide
Glipizide	Naratriptan	Sumatriptan	Probenecid

Chow TG, Khan DA. Clin Rev Allergy Immunol. 2022;62(3):400-12.

66

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

# Absence of Cross-Reactivity between Sulfonamide Antibiotics and Sulfonamide Nonantibiotics

Brian L. Strom, M.D., M.P.H., Rita Schinnar, M.P.A., Andrea J. Apter, M.D., David J. Margolis, M.D., Ph.D., Ebbing Lautenbach, M.D., M.P.H., M.S.C.E., Sean Hennessy, Pharm.D., Ph.D., Warren B. Bilker, Ph.D., and Dan Pettitt, D.V.M.

N Engl J Med. 2003;349(17):1628-35.

67

## 1 or 2 Step Sulfonamide Challenges


195 non-HIV patients with sulfonamide allergy history  
 173 underwent 1-step challenge  
 Low risk histories  
 > 5yrs from reaction  
 95% passed  
 22 underwent 2-step challenge  
 Higher risk history  
 86% passed

J Allergy Clin Immunol Pract. 2020;8(2):757-60.e4.

Mayo Clinic study of 52 patients showed 96% passed challenge  
 J Allergy Clin Immunol Pract. 2022;10(4):1107-9.

### Oral challenge with trimethoprim-sulfamethoxazole in patients with "sulfa" antibiotic allergy

Matthew S. Krantz, MD<sup>a,\*</sup>,  
 Cosby A. Stone, Jr., MD, MPH<sup>b,\*</sup>, Andrew Abreo, MD<sup>b</sup>,  
 and Elizabeth J. Phillips, MD<sup>b,c,d,e,f</sup>



68

**PRACTICE CHANGER****1-Step  
Sulfonamide  
Challenge  
When  
Delabeling Is  
Needed****Consensus Based Statement**

- We suggest that **for patients with a history of benign cutaneous reactions** (e.g. morbilliform drug eruption, urticaria) **to sulfonamide antibiotics that occurred > 5 years ago, a 1-step drug challenge with trimethoprim-sulfamethoxazole be performed when there is a need to delabel a sulfonamide antibiotic allergy.**

**Strength of Recommendation**

- Conditional

**Certainty of Evidence**

- Low

Khan DA et al. J Allergy Clin Immunol 2022;150(6):1333-93.

69

**Key Point #7**

**When There Is No  
Alternative  
A Drug Desensitization  
May Be Considered But  
It Is Not Permanent**

70

## Drug Desensitizations

**Indicated for patients with:**

- High likelihood or confirmed drug allergy
- In need of culprit drug where no alternative therapy exists

**Many Rapid Drug Desensitizations**

- Antibiotics
- Chemotherapeutics, monoclonal Abs
- Aspirin
- Others

71

**Table 2. Three-Bag, 12-Step Intravenous Penicillin Desensitization Protocol.\***

Step	Bag	Rate <i>ml/hr</i>	Time† <i>min</i>	Volume Infused <i>ml</i>	Dose Administered <i>units</i>	Cumulative Dose
1	1	2.0	15	0.50	200.0	200.0
2	1	5.0	15	1.25	500.0	700.0
3	1	10.0	15	2.50	1,000.0	1,700.0
4	1	20.0	15	5.00	2,000.0	3,700.0
5	2	5.0	15	1.25	5,000.0	8,700.0
6	2	10.0	15	2.50	10,000.0	18,700.0
7	2	20.0	15	5.00	20,000.0	38,700.0
8	2	40.0	15	10.00	40,000.0	78,700.0
9	3	10.0	15	2.50	98,032.5	176,732.5
10	3	20.0	15	5.00	196,065.0	372,797.5
11	3	40.0	15	10.00	392,130.0	764,927.5
12	3	80.0	61.875	82.50	3,235,072.5	4,000,000.0

Castells M, Khan DA, Phillips EJ. Penicillin Allergy. N Engl J Med. 2019;381(24):2338-51.

72

The image shows two covers of the journal 'The Journal of Allergy and Clinical Immunology: In Practice'. The left cover is titled 'Drug Allergy Resources' and lists various resources including 'Practical Guidance for the Evaluation and Management of Drug Hypersensitivity', 'Fall 2021 Update to the Drug Hypersensitivity Practical Guidance Resource', 'Skin Testing for Drug Hypersensitivity', 'Controversies in Drug Allergy', 'Drug Allergy Collections', and 'Penicillin and Cephalosporin Cross-Reactivity Table'. The right cover is titled 'Practical Guidance for the Evaluation and Management of Drug Hypersensitivity' and is an American Academy of Allergy, Asthma & Immunology Work Group Report. It features a circular graphic with the text 'Skin Testing Challenge Desensitization' and lists the Presidential Initiative of Thomas A. Fleisher, MD, FAAAAI, and several Chief and Coordinating Editors.

# Other Drug Allergy Resources

73

The flowchart consists of four colored boxes connected by downward-pointing arrows. The first box (red) states: 'There are many types of antibiotic reactions, cutaneous features can help determine testing/management/prognosis'. The second box (purple) states: 'Most patients labeled with antibiotic allergy are not allergic'. The third box (dark blue) states: 'The label of penicillin allergy is associated with adverse health outcomes and can be removed through testing in >98% cases'. The fourth box (teal) states: 'Antibiotic challenges can be performed to prove tolerance, even by non-allergists'. To the right of the flowchart is a large light blue vertical rectangle with the word 'Summary' written in white.

74